The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...